Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 5:18 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Geriatric Population Clear all
Completed Phase 3 Interventional Results available

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor

NCT02347657
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
VX-661 Plus Ivacaftor Combination, Ivacaftor, VX-661 Plus Ivacaftor Combination Placebo, Ivacaftor placebo
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
12 Years and older
Enrollment
510 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
27
States / cities
Little Rock, Arkansas • Long Beach, California • Denver, Colorado + 24 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2018 · Synced Jul 23, 2026, 5:18 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Dasotraline in Children 6 to 12 Years Old With Attention-Deficit Hyperactivity Disorder (ADHD) in a Simulated Classroom Setting.

NCT03231800
View directory record Official record
Conditions
Attention-Deficit Hyperactivity Disorder (ADHD)
Interventions
dasotraline, Placebo
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
6 Years to 12 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
8
States / cities
Newport Beach, California • Bradenton, Florida • Maitland, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2020 · Synced Jul 23, 2026, 5:18 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Mindfulness for Cognition in Early-stage Alzheimer's Disease

NCT06792877
View directory record Official record
Conditions
Mild Cognitive Impairment (MCI), Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease, TBI (Traumatic Brain Injury), Aging, Healthy Elderly, Alzheimer&Amp;Amp;#39;s Dementia (AD)
Interventions
Mindfulness Intervention, Waitlist then mindfulness
Behavioral
Lead sponsor
VA Boston Healthcare System
Federal
Eligibility
50 Years to 100 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 26, 2025 · Synced Jul 23, 2026, 5:18 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Valproic Acid in Subjects With Intact Cognition - Proof of Concept Study

NCT01729598
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Valproic Acid, Placebo
Drug
Lead sponsor
Gregory Jicha, 323-5550
Other
Eligibility
65 Years to 90 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Oct 8, 2019 · Synced Jul 23, 2026, 5:18 AM EDT
Terminated Phase 4 Interventional Results available

Simplified Insulin Regimen for the Elderly

NCT03660553
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Insulin Glargine, Insulin Aspart, Insulin Lispro
Drug
Lead sponsor
University of Miami
Other
Eligibility
65 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
South Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 11, 2023 · Synced Jul 23, 2026, 5:18 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional

A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy.

NCT05523167
View directory record Official record
Conditions
Active Idiopathic Inflammatory Myopathy, Myositis, Dermatomyositis, Polymyositis, Immune-Mediated Necrotizing Myopathy, Antisynthetase Syndrome
Interventions
EFG PH20 SC, PBO
Biological · Other
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
265 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
40
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Beverly Hills, California + 35 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2025 · Synced Jul 23, 2026, 5:18 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study in Preschool Children Aged 4-5 Years With Attention-deficit/Hyperactivity Disorder (ADHD)

NCT03260205
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder (ADHD)
Interventions
Placebo, SPD489 (Lisdexamfetamine dimesylate), SPD489
Drug
Lead sponsor
Shire
Industry
Eligibility
4 Years to 5 Years
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
48
States / cities
Dothan, Alabama • Little Rock, Arkansas • Colton, California + 39 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2021 · Synced Jul 23, 2026, 5:18 AM EDT
Terminated No phase listed Observational

Acute Viral Respiratory Infections in Elderly

NCT00170495
View directory record Official record
Conditions
Respiratory Infections, Acute
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
65 Years and older
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 26, 2010 · Synced Jul 23, 2026, 5:18 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Sanofi H1N1 Influenza Vaccine Administered at Different Dose Levels With and Without AS03 Adjuvant in Healthy Adult and Elderly Populations

NCT00963157
View directory record Official record
Conditions
Influenza
Interventions
AS03, Influenza Virus Vaccine, Monovalent A/H1N1 A/California/7/2009 NYMC X-179A
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
789 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
7
States / cities
Stanford, California • Decatur, Georgia • Iowa City, Iowa + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2014 · Synced Jul 23, 2026, 5:18 AM EDT
Completed Phase 2 Interventional Results available

Pharmacokinetics, Safety and Efficacy of Nemolizumab in Participants With Moderate-to-Severe Atopic Dermatitis

NCT04921345
View directory record Official record
Conditions
Moderate-to-Severe Atopic Dermatitis
Interventions
Nemolizumab
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
2 Years to 12 Years
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
14
States / cities
Fountain Valley, California • San Diego, California • Vista, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Jul 23, 2026, 5:18 AM EDT
Completed Phase 2 Interventional Results available

A Study to Investigate Efficacy and Safety of OG-6219 BID in 3 Dose Levels Compared With Placebo in Participants Aged 18 to 49 With Moderate to Severe Endometriosis-related Pain

NCT05560646
View directory record Official record
Conditions
Endometriosis
Interventions
OG-6219, Placebo
Drug
Lead sponsor
Organon and Co
Industry
Eligibility
18 Years to 49 Years · Female only
Enrollment
354 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
27
States / cities
Birmingham, Alabama • Los Angeles, California • Orange, Connecticut + 22 more
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Jul 23, 2026, 5:18 AM EDT
Recruiting Phase 2 Interventional

A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease

NCT06500702
View directory record Official record
Conditions
Focal Segmental Glomerulosclerosis, Glomerulonephritis Minimal Lesion
Interventions
frexalimab, brivekimig, rilzabrutinib, placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
16 Years to 75 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
16
States / cities
Birmingham, Alabama • Orange, California • San Francisco, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Jul 23, 2026, 5:18 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate Safety and Efficacy of Dapagliflozin and Saxagliptin in Patients With Type 2 Diabetes Mellitus (T2DM) Aged 10 to Below 18 Years Old

NCT03199053
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Dapagliflozin, Saxagliptin, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
10 Years to 18 Years
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
20
States / cities
Sacramento, California • New Haven, Connecticut • Hialeah, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2024 · Synced Jul 23, 2026, 5:18 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Brimonidine Tartrate Ophthalmic Solution in Adult and Geriatric Participants With Ocular Redness

NCT01959230
View directory record Official record
Conditions
Hyperemia
Interventions
Brimonidine Tartrate, Vehicle, Sodium Fluorescein, Fluorescein Sodium and Benoximate Hydrocholoride Ophthalmic Solution USP
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 22, 2019 · Synced Jul 23, 2026, 5:18 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Feasibility Study Evaluating the Use of SafeBreak Vascular in the Geriatric Trauma Population

NCT03505957
View directory record Official record
Conditions
IV Dislodgement
Interventions
SafeBreak Vascular
Device
Lead sponsor
Lineus Medical
Industry
Eligibility
55 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 4, 2020 · Synced Jul 23, 2026, 5:18 AM EDT
Completed Phase 3 Interventional

Safety and Efficacy of ADDERALL XR in the Treatment of Adolescents Aged 13-17 With Attention Deficit Hyperactivity Disorder (ADHD)

NCT00507065
View directory record Official record
Conditions
ADHD
Interventions
Mixed salts of a single-entity amphetamine (ADDERALL XR), Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
13 Years to 17 Years
Enrollment
329 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 7, 2021 · Synced Jul 23, 2026, 5:18 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Activity Monitoring and Counseling in a Geriatric Population

NCT01502007
View directory record Official record
Conditions
Overweight, Obesity
Interventions
Accelerometer feedback and lifestyle counseling, Accelerometer without Feedback
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
65 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 5, 2014 · Synced Jul 23, 2026, 5:18 AM EDT
Terminated Phase 3 Interventional

Efficacy and Safety of Milnacipran in the Treatment of Fibromyalgia in an Elderly Population

NCT01418651
View directory record Official record
Conditions
Fibromyalgia
Interventions
Savella
Drug
Lead sponsor
Banner Health
Other
Eligibility
65 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Sun City, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 16, 2011 · Synced Jul 23, 2026, 5:18 AM EDT
Completed No phase listed Observational

Parkinson's Genes and Environment Study

NCT00367900
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Not listed
Lead sponsor
National Institute of Environmental Health Sciences (NIEHS)
NIH
Eligibility
50 Years and older
Enrollment
3,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
1
States / cities
Research Triangle Park, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 17, 2021 · Synced Jul 23, 2026, 5:18 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Targeting Aging With a Ketone Ester for Function in Frailty

NCT06645847
View directory record Official record
Conditions
Frail Elderly, Aging, Immune Function, Muscle Function
Interventions
Ketone ester, Placebo Comparator: Non-ketone placebo
Other
Lead sponsor
Buck Institute for Research on Aging
Other
Eligibility
65 Years and older
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
3
States / cities
Novato, California • Farmington, Connecticut • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Jul 23, 2026, 5:18 AM EDT
Completed Phase 3 Interventional

Depression Study In Elderly Patients

NCT00067444
View directory record Official record
Conditions
Depressive Disorder, Major, Major Depressive Disorder (MDD)
Interventions
Paroxetine CR
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
60 Years and older
Enrollment
560 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
46
States / cities
Little Rock, Arkansas • Anaheim, California • Beverly Hills, California + 40 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2016 · Synced Jul 23, 2026, 5:18 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Sling Use and Functional Mobility in a Geriatric Population

NCT03921619
View directory record Official record
Conditions
Mobility Limitation
Interventions
Shoulder Sling
Device
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
65 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Nov 8, 2021 · Synced Jul 23, 2026, 5:18 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Evaluating Multiple Doses Of GSI-953 Within The Elderly Population

NCT00547560
View directory record Official record
Conditions
Healthy
Interventions
GSI-953
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
65 Years and older
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 3, 2011 · Synced Jul 23, 2026, 5:18 AM EDT
Completed Phase 2 Interventional Results available

Efficacy And Safety Of CX516 In Elderly Participants With Mild Cognitive Impairment.

NCT00040443
View directory record Official record
Conditions
Mild Cognitive Impairment
Interventions
CX516, Placebo
Drug
Lead sponsor
RespireRx
Industry
Eligibility
55 Years to 85 Years
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
8
States / cities
Peoria, Arizona • Irvine, California • Los Angeles, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2018 · Synced Jul 23, 2026, 5:18 AM EDT